WO2009002931A3 - Methods and uses thereof of prosaposin - Google Patents

Methods and uses thereof of prosaposin Download PDF

Info

Publication number
WO2009002931A3
WO2009002931A3 PCT/US2008/067899 US2008067899W WO2009002931A3 WO 2009002931 A3 WO2009002931 A3 WO 2009002931A3 US 2008067899 W US2008067899 W US 2008067899W WO 2009002931 A3 WO2009002931 A3 WO 2009002931A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
metastasis
methods
angiogenesis
tumor
Prior art date
Application number
PCT/US2008/067899
Other languages
French (fr)
Other versions
WO2009002931A2 (en
Inventor
Randolph Watnick
Original Assignee
Children's Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP16161100.9A priority Critical patent/EP3127549B1/en
Priority to AU2008268461A priority patent/AU2008268461B2/en
Priority to EP08771746.8A priority patent/EP2190448B1/en
Priority to EP19207732.9A priority patent/EP3666284A1/en
Priority to CA2692171A priority patent/CA2692171C/en
Application filed by Children's Medical Center Corporation filed Critical Children's Medical Center Corporation
Publication of WO2009002931A2 publication Critical patent/WO2009002931A2/en
Priority to US12/640,788 priority patent/US20100144603A1/en
Priority to US13/516,511 priority patent/US10267799B2/en
Publication of WO2009002931A3 publication Critical patent/WO2009002931A3/en
Priority to AU2013203640A priority patent/AU2013203640B2/en
Priority to AU2017201638A priority patent/AU2017201638B2/en
Priority to US16/379,193 priority patent/US10670600B2/en
Priority to US16/867,560 priority patent/US12117448B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pathology (AREA)

Abstract

The invention relates to methods for treating of tumor metastasis, methods for preventing, inhibiting, and predicting tumor recurrence and tumor metastasis, and methods of preventing cancer development for one at risk of developing cancer, for one diagnosed with a benign cancer, and/or for one diagnosed with malignant cancer. The invention also relates to methods of treating angiogenesis-dependent diseases and disorders. In addition, the invention provides: (1) a method for screening for tumor/cancer derived angiogenesis and metastasis factors; (2) a method for screening for compounds that inhibit angiogenesis and metastasis; (3) a method for screening for compounds that promote anti- angiogenesis and anti-metastasis activities; (4) a method for cancer prognosis evaluation; (5) a method for predicting the tissue specificity of a metastastic cancer; (6) a method for determining likelihood of metastasis; and (7) a method for cancer prognosis evaluation by the surveillance of metastasis development.
PCT/US2008/067899 2007-06-22 2008-06-23 Methods and uses thereof of prosaposin WO2009002931A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP16161100.9A EP3127549B1 (en) 2007-06-22 2008-06-23 Methods and uses thereof of a fragment of saposin a
AU2008268461A AU2008268461B2 (en) 2007-06-22 2008-06-23 Methods and uses thereof of prosaposin
EP08771746.8A EP2190448B1 (en) 2007-06-22 2008-06-23 Methods and uses thereof of a fragment of saposin a
EP19207732.9A EP3666284A1 (en) 2007-06-22 2008-06-23 Methods and uses thereof of a fragment of saposin a
CA2692171A CA2692171C (en) 2007-06-22 2008-06-23 Methods and uses thereof of prosaposin
US12/640,788 US20100144603A1 (en) 2007-06-22 2009-12-17 Methods and uses thereof of prosaposin
US13/516,511 US10267799B2 (en) 2007-06-22 2010-12-17 Saposin-A derived peptides and uses thereof
AU2013203640A AU2013203640B2 (en) 2007-06-22 2013-04-11 Methods and uses thereof of prosaposin
AU2017201638A AU2017201638B2 (en) 2007-06-22 2017-03-09 Methods and uses thereof of prosaposin
US16/379,193 US10670600B2 (en) 2007-06-22 2019-04-09 Saposin-A derived peptides and uses thereof
US16/867,560 US12117448B2 (en) 2007-06-22 2020-05-05 Saposin-A derived peptides and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93679207P 2007-06-22 2007-06-22
US60/936,792 2007-06-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/640,788 Continuation-In-Part US20100144603A1 (en) 2007-06-22 2009-12-17 Methods and uses thereof of prosaposin

Publications (2)

Publication Number Publication Date
WO2009002931A2 WO2009002931A2 (en) 2008-12-31
WO2009002931A3 true WO2009002931A3 (en) 2011-03-03

Family

ID=40186257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/067899 WO2009002931A2 (en) 2007-06-22 2008-06-23 Methods and uses thereof of prosaposin

Country Status (5)

Country Link
US (4) US20100144603A1 (en)
EP (3) EP3127549B1 (en)
AU (1) AU2008268461B2 (en)
CA (2) CA2692171C (en)
WO (1) WO2009002931A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc System and method for determining individualized medical intervention for a disease state
CA2692171C (en) * 2007-06-22 2019-10-22 Randolph Watnick Methods and uses thereof of prosaposin
EP2543389A3 (en) 2007-08-02 2013-04-24 Gilead Biologics, Inc. Methods and compositions inhibiting a lysyl oxidase (-like) protein for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US20100021997A1 (en) * 2008-02-21 2010-01-28 Shahriar Koochekpour Biologically active recombinant human saposin C and PSAP
EP2730662A1 (en) 2008-11-12 2014-05-14 Caris Life Sciences Luxembourg Holdings Methods and systems of using exosomes for determining phenotypes
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
KR20120063488A (en) 2009-08-21 2012-06-15 길리아드 바이오로직스, 인크. Catalytic domains from lysyl oxidase and loxl2
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
RU2012110587A (en) * 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. THERAPEUTIC METHODS AND COMPOSITIONS
RU2015124151A (en) * 2009-08-21 2015-12-27 Джилид Байолоджикс, Инк. METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROUS LUNG DISEASES
CA2771774A1 (en) * 2009-08-21 2011-02-24 Gilead Biologics, Inc. In vitro screening assays
EP3366695B1 (en) * 2009-12-17 2021-07-07 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
AU2011212830B2 (en) 2010-02-04 2014-05-22 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2) and methods of use therefor
CN103237901B (en) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 For treating the biomarker of diagnosis
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
WO2012154825A1 (en) * 2011-05-09 2012-11-15 Thornton Sherry L Method for imaging a site of arthritis in an animal
EP3560509B1 (en) 2011-12-22 2024-01-31 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
US9921224B2 (en) 2013-03-14 2018-03-20 Children's Medical Center Corporation Use of CD36 to identify cancer subjects for treatment
AU2015235978B2 (en) * 2014-03-26 2019-08-08 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
CN110650751A (en) * 2017-03-22 2020-01-03 儿童医学中心公司 LRP1 binding agents and uses thereof
WO2018175765A1 (en) * 2017-03-22 2018-09-27 Children's Medical Center Corporation Prss2 inhibition
CA3078464A1 (en) * 2017-10-03 2019-04-11 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
CN115032286B (en) * 2021-03-08 2024-08-13 江成鸿 Application of composition in preparation of medicines for diagnosing infantile hemangioma and/or monitoring progress and prognosis of infantile hemangioma, kit and medicines
WO2023114169A1 (en) * 2021-12-13 2023-06-22 Hessian Labs, Inc. Methods for determining the prognosis and stage of a disease or disorder

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003821A1 (en) * 1993-07-30 1995-02-09 The Regents Of The University Of California Prosaposin and cytokine-derived peptides as therapeutic agents
US5714459A (en) * 1993-07-30 1998-02-03 Myelos Neurosciences Corp. Use of prosaposin and neurotrophic peptides derived therefrom
WO2000002902A1 (en) * 1998-07-13 2000-01-20 Gill Parkash S Novel inhibitors of angiogenesis and tumor growth
WO2002024952A1 (en) * 2000-09-22 2002-03-28 Clinomics Biosciences, Inc. Profile array substrates
US20020177551A1 (en) * 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2004084930A1 (en) * 2003-03-26 2004-10-07 Develogen Aktiengesellschaft Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
WO2004096159A2 (en) * 2003-04-28 2004-11-11 Children's Hospital Medical Center Saposin c-dops: a novel anti-tumor agent

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548257A (en) 1895-10-22 Hay rake and loader
US684780A (en) 1901-02-28 1901-10-22 Newton S Beale Corn-crib.
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3837376A (en) 1971-06-01 1974-09-24 Metropolitan Pathology Labor I Blood serum collection tube and method
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3413608A1 (en) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt IMPLANTABLE PREPARATIONS OF REGULATORY PEPTIDES WITH CONTROLLED RELEASE AND METHOD FOR THE PRODUCTION THEREOF
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4656035A (en) 1984-12-21 1987-04-07 University Of Tennessee Research Corporation Method of separating blood platelets
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (en) 1987-02-09 1996-03-13 株式会社ビタミン研究所 Antitumor agent-embedded liposome preparation
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US5180816A (en) 1988-08-24 1993-01-19 Centocor One vial method for labeling protein/linker conjugates with technetium-99M
US5118937A (en) 1989-08-22 1992-06-02 Finnigan Mat Gmbh Process and device for the laser desorption of an analyte molecular ions, especially of biomolecules
US5045694A (en) 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
AU1248292A (en) 1990-12-06 1992-07-08 Affymax Technologies N.V. Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
WO1992020820A1 (en) 1991-05-15 1992-11-26 Vanderbilt University Method to determine metastatic potential of tumor cells
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU681082B2 (en) 1992-05-06 1997-08-21 Gen-Probe Incorporated Nucleic acid sequence amplification method, composition and kit
DK0700521T3 (en) 1993-05-28 2003-09-29 Baylor College Medicine Process and mass spectrometer for desorption and ionization of analyzers
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
GB9608130D0 (en) 1996-04-19 1996-06-26 Univ Sheffield Adam proteins and uses thereof
US5817752A (en) * 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
WO1999012559A1 (en) * 1997-09-09 1999-03-18 The Regents Of The University Of California Inhibition of apoptotis using prosaposin receptor agonists
US6423685B1 (en) 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6638911B1 (en) 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
CA2255430C (en) 1998-12-10 2003-08-26 P. Wedge Co. Ltd. A swivel device for a windcone tower assembly
US20020182702A1 (en) 1999-05-27 2002-12-05 Ruben Steven M. ADAM polynucleotides, polypeptides, and antibodies
EP1206494B1 (en) 1999-08-02 2004-11-03 Synt:Em S.A. Computational design methods for making molecular mimetics
AU7262700A (en) 1999-09-07 2001-04-10 Viventia Biotech Inc. Enhanced phage display library of human vh fragments and methods for producing same
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
EP1946783B1 (en) 2000-03-09 2011-09-07 CaridianBCT, Inc. Extracorporeal blood processing apparatus
CN1463291A (en) 2001-04-19 2003-12-24 赛弗根生物系统股份有限公司 Biomolecule characterization using mass spectormetry and affinity tags
US7074901B2 (en) 2001-05-25 2006-07-11 Serono Genetics Institute S.A. Isolated human vCOL16A1 polypeptide and fragments thereof
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
US8068987B2 (en) 2001-08-13 2011-11-29 Bg Medicine, Inc. Method and system for profiling biological systems
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
AU2003239152A1 (en) 2002-04-23 2003-11-10 Millipore Corporation Sample preparation of biological fluids for proteomic applications
US20030205538A1 (en) 2002-05-03 2003-11-06 Randel Dorian Methods and apparatus for isolating platelets from blood
WO2003102018A2 (en) 2002-06-03 2003-12-11 The Institute For Systems Biology Methods for quantitative proteome analysis of glycoproteins
US20040219609A1 (en) * 2002-07-12 2004-11-04 Day Anthony G. Methods for modulating proteins not previously known as proteases
US7166691B2 (en) * 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
AU2006304605A1 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
CA2692171C (en) 2007-06-22 2019-10-22 Randolph Watnick Methods and uses thereof of prosaposin
EP3366695B1 (en) 2009-12-17 2021-07-07 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
EP3560509B1 (en) 2011-12-22 2024-01-31 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
US9921224B2 (en) 2013-03-14 2018-03-20 Children's Medical Center Corporation Use of CD36 to identify cancer subjects for treatment
AU2015235978B2 (en) 2014-03-26 2019-08-08 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003821A1 (en) * 1993-07-30 1995-02-09 The Regents Of The University Of California Prosaposin and cytokine-derived peptides as therapeutic agents
US5714459A (en) * 1993-07-30 1998-02-03 Myelos Neurosciences Corp. Use of prosaposin and neurotrophic peptides derived therefrom
WO2000002902A1 (en) * 1998-07-13 2000-01-20 Gill Parkash S Novel inhibitors of angiogenesis and tumor growth
US20020177551A1 (en) * 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2002024952A1 (en) * 2000-09-22 2002-03-28 Clinomics Biosciences, Inc. Profile array substrates
WO2004084930A1 (en) * 2003-03-26 2004-10-07 Develogen Aktiengesellschaft Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
WO2004096159A2 (en) * 2003-04-28 2004-11-11 Children's Hospital Medical Center Saposin c-dops: a novel anti-tumor agent

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DE FRAIPONT F ET AL: "Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: Correlation with genotypic alterations", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 2000 US LNKD- DOI:10.1210/JC.85.12.4734, vol. 85, no. 12, 2000, pages 4734 - 4741, XP002591317, ISSN: 0021-972X *
DOLL J A ET AL: "THROMBOSPONDIN-1, VASCULAR ENDOTHELIAL GROWTH FACTOR AND FIBROBLAST GROWTH FACTOR-2 ARE KEY FUNCTINAL REGULATORS OF ANGIOGENESIS IN THE PROSTATE", PROSTATE, WILEY-LISS, NEW YORK, NY, US LNKD- DOI:10.1002/PROS.10025, vol. 49, 1 December 2001 (2001-12-01), pages 293 - 305, XP008070850, ISSN: 0270-4137 *
HU SIYI ET AL: "Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 1, 4 February 2010 (2010-02-04), pages 30, XP021067981, ISSN: 1476-4598 *
KANG SOO-YOUNG ET AL: "Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 21 JUL 2009 LNKD- PUBMED:19581582, vol. 106, no. 29, 21 July 2009 (2009-07-21), pages 12115 - 12120, XP002591318, ISSN: 1091-6490 *
KOOCHEKPOUR S ET AL: "Amplification and overexpression of prosaposin in prostate cancer", GENES CHROMOSOMES AND CANCER 200512 US LNKD- DOI:10.1002/GCC.20249, vol. 44, no. 4, December 2005 (2005-12-01), pages 351 - 364, XP002591319, ISSN: 1045-2257 *
PANIGONE S ET AL: "Up-regulation of prosaposin by the retinoid HPR and its effect on ceramide production and integrin receptors.", THE FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY JUN 2001 LNKD- PUBMED:11387262, vol. 15, no. 8, June 2001 (2001-06-01), pages 1475 - 1477, XP002591316, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
EP2190448A2 (en) 2010-06-02
US20130072425A1 (en) 2013-03-21
CA3056116A1 (en) 2008-12-31
WO2009002931A2 (en) 2008-12-31
EP3127549A1 (en) 2017-02-08
US20100144603A1 (en) 2010-06-10
AU2008268461B2 (en) 2015-04-09
CA2692171C (en) 2019-10-22
US20210102945A1 (en) 2021-04-08
CA2692171A1 (en) 2008-12-31
EP3666284A1 (en) 2020-06-17
US20200081007A1 (en) 2020-03-12
US10670600B2 (en) 2020-06-02
US10267799B2 (en) 2019-04-23
AU2008268461A1 (en) 2008-12-31
EP2190448B1 (en) 2016-04-20
EP3127549B1 (en) 2019-12-18
US12117448B2 (en) 2024-10-15

Similar Documents

Publication Publication Date Title
WO2009002931A3 (en) Methods and uses thereof of prosaposin
WO2006052823A3 (en) Biomarkers for prostate cancer metastasis
EA200971079A1 (en) GENETIC OPTIONS IN CHR5P12 AND 10Q26 AS MARKERS FOR RISK ASSESSMENT, DIAGNOSIS, PREDICTION AND TREATMENT OF BREAST
WO2006012646A3 (en) Amacr cancer markers
WO2007006408A3 (en) Methods and kits for predicting and monitoring direct response to cancer therapy
Kocián et al. Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
WO2008063769A3 (en) Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
WO2009108917A3 (en) Markers for improved detection of breast cancer
WO2006105486A3 (en) Novel tumor suppressor gene and compositions and methods for making and using the same
WO2007112330A3 (en) Compositions and methods for detection, prognosis and treatment of colon cancer
WO2007123772A3 (en) Genes involved in estrogen metabolism
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
WO2010125566A3 (en) Markers for cancer detection
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
WO2007081680A3 (en) Microrna expression abnormalities in pancreatic endocrine and acinar tumors
WO2009036427A3 (en) Prostate cancer biomarkers
WO2006047482A3 (en) Method for determining the diagnosis, malignant potential, and biologic behavior of pancreatic cysts using cyst aspirate
WO2010018601A3 (en) Genetic variants predictive of cancer risk
WO2007010089A3 (en) Cancer specific glycans and use thereof
WO2006133923A3 (en) Diagnosis, prognosis and prediction of recurrence of breast cancer
WO2005119260A3 (en) Methods for predicting and monitoring response to cancer therapy
HK1145342A1 (en) Prognosis prediction for melanoma cancer
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
ATE525484T1 (en) SLCO1B3 GENOTYPE

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008268461

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2692171

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008771746

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008268461

Country of ref document: AU

Date of ref document: 20080623

Kind code of ref document: A